Eval GRADE ECA CATT: Ranibizumab vs Bevacizumab para degeneración macular neovascular asociada a la edad
Grupo Evalmed, 2012
DESCARGAR PDF
Eval GRADE ECA CATT 1y, ranibizumab vs bevacizumab, DMAE
Eval GRADE ECA CATT 1y, ranibizumab vs bevacizumab, DMAE